Hashim Ahmed

Biography

Professor Hashim Ahmed is currently Chair of Urology at Imperial College London. Hashim is an internationally renowned expert in prostate cancer diagnosis, imaging and biopsy as well as minimally invasive therapies for prostate cancer such as HIFU and cryotherapy – either whole-gland or focal therapy for primary prostate cancer or radiorecurrent disease. He has taught dozens of surgeons in these techniques in the UK and around the world and given numerous invited international lectures in this area. He has an extensive research portfolio with about £6M in grant income as a principal applicant and co-applicant to a research programme of approximately £14M. He has published over 150 peer-reviewed papers in areas that have led to key changes in the way we diagnose and treat men with localised prostate cancer. He currently holds a £2.1M Wellcome Trust Senior Clinical Research Fellowship and is Director of the Wellcome Trust Prostate Research in Imaging and Surgical Methodology (PRISM) Programme. Detailed Biography Hashim qualified from the University of Oxford where he attended St Peters College and Linacre College. Whilst he was a student he was awarded the William Osler Prize in Medicine. He then held house office posts in Queen Elizabeth Hospital, Birmingham and University Hospitals Manchester before returning to Oxford for an Anatomy Prosector post. Hashim then held senior house jobs in surgery on the Royal Free Hospital, London rotation followed by specialist registrar posts at West Middlesex Hospital, Charing Cross Hospital/Imperial College, University College Hospital and Watford General Hospital as part of the Imperial College Urology Rotation. He was a Pelican Cancer Foundation Research Fellow followed by a MRC Clinician Research Training fellowship at University College London at which time a number of imaging and focal therapy trials were started. His research interests are in Health Technology Evaluation including multi-parametric MRI, Histoscanning, Tissue Type Imaging, as well as therapeutic interventions such as high intensity focused ultrasound, irreversible electroporation, photodynamic therapy, cryotherapy and radiofrequency ablation. He has completed numerous phase I/II clinical trials evaluating the role of focal therapy in prostate cancer and is lead PI and Co-PI in a number of multicentre trials including the UK NIHR-HTA funded study NCRN PROMIS study evaluating the role of multi-parametric MRI in men with a raised PSA using Template Prostate Mapping as the reference standard as well as NCRN INDEX, a multicentre focal therapy study using HIFU with 3 year follow-up and NCRN FORECAST. He previously held a £1.2M MRC Clinician Scientist Fellowship for 5 years and currently holds a £2M Senior Clinical Research Fellowship from the Wellcome Trust. His total grant income is £5M as lead applicant and £8M in total as co-applicant. He has been visiting professor to UCLA, Tokyo, Weill-Cornell and Detroit universities and has given over 30 plenary lectures at national and international urology, oncology and imaging meetings.

Research Interest

Urology